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Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a systemic disease that is associated with increased
serum levels of markers of systemic inﬂammation. The triggering receptor expressed on myeloid cells 1 (TREM-1) is a recently
identiﬁed activating receptor on neutrophils, monocytes, and macrophage subsets. TREM-1 expression is upregulated by mi-
crobial products such as the toll-like receptor ligand lipoteichoic acid of Gram-positive or lipopolysaccharides of Gram-negative
bacteria. In the present study, sera from 12 COPD patients (GOLD stages I–IV, FEV1 51 ± 6%) and 10 healthy individuals were
retrospectively analyzed for soluble TREM-1 (sTREM-1) using a newly developed ELISA. In healthy subjects, sTREM-1 levels
were low (median 0.25 ng/mL, range 0–5.9 ng/mL). In contrast, levels of sTREM-1 in sera of COPD patients were signiﬁcantly
increased(median11.68ng/mL,range6.2–41.9ng/mL,P<. 05). Furthermore,serumlevels ofsTREM-1showed asigniﬁcant neg-
ative correlation with lung function impairment. In summary, serum concentrations of sTREM-1 are increased in patients with
COPD.ProspectivestudiesarewarrantedtoevaluatetherelevanceofsTREM-1asapotentialmarkerofthediseaseinpatientswith
COPD.
Copyright © 2007 Markus P. Radsak et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is charac-
terized by progressive development for the most part irre-
versibleairﬂowobstructionthatinvolvesanabnormalairway
inﬂammatory response [1]. The clinical course of COPD is
typically dominated by intermittent exacerbations, responsi-
ble for the majority of the disease-associated morbidity and
mortality [2, 3].
In recent years COPD has more and more been charac-
terized asasystemicinﬂammatorydisease. Severalmediators
have been found increased in blood of COPD patients in-
dicating persistent systemic inﬂammation [4]. The origin of
this inﬂammatory response is unknown but several diﬀerent
mechanisms including smoking itself, a cytokine “spill over”
from the lungs, tissue hypoxia, and genetic factors [5]o rpe r -
sistent bacterial colonization of the airways [6–10]h a v eb e e n
suggested.
The triggering receptor expressed on myeloid cells
(TREM-1) is a recently identiﬁed activating receptor on neu-
trophil granulocytes (PMN), monocytes, and macrophage
subsets[11,12].TheexpressionofTREM-1isupregulatedby
microbial products, that is, by toll-like receptor ligands such
as lipoteichoic acid (LTA) of Gram-positive or lipopolysac-
charide (LPS) of Gram-negative bacteria. Ligation of TREM-
1 is synergistic with TLR agonists on the activation of recep-
tor bearing cells for the release of inﬂammatory mediators
like TNF-α and IL-8 and the initiation of neutrophil respi-
ratory burst [11, 13]. We recently reported that a natural lig-
andforTREM-1ispresentonplatelets,althoughitstillneeds
to be identiﬁed [14]. The biological signiﬁcance of TREM-
1i na c u t ei n ﬂ a m m a t o r yr e s p o n s e si sd o c u m e n t e di nm o u s e2 Clinical and Developmental Immunology
models for septic shock, where competition of TREM-1 with
a recombinant soluble TREM-1 fusion protein or an putative
receptor blocking peptide derived from a conserved region
of TREM-1 saved mice from lethal LPS challenge or bacterial
sepsis [15–17].
TREM-1 is also produced in a soluble form [18]a n dr e -
leased in humans after endotoxin exposition [19]o ri np a -
tientssuﬀeringfromseverepneumonia[20]orsepsis[21].In
these critically ill patients, elevated levels of soluble TREM-1
(sTREM-1) are detectable in bronchoalveolar lavage (BAL)
ﬂuid or in plasma, respectively, and have a high accuracy
and sensitivity in detecting microbial infections as under-
lying disease [20, 22, 23]. In addition, the time course of
sTREM-1levelsmightbeausefulparameterinpredictingthe
outcome in sepsis patients [24, 25]. However, a limitation of
these studies is certainly that only critically ill patients were
examined. A recent study by Richeldi et al.demonstrates that
an increase in sTREM-1 is also detectable in patients suﬀer-
ing from community acquired pneumonia caused by extra-
cellular bacteria, but not in patients with interstitial lung dis-
ease or tuberculosis [26]. Furthermore, sTREM-1 has been
associated with major abdominal surgery and peptic ulcer
disease [27, 28].
In the present study, we developed a sensitive enzyme-
linked immunosorbent assay (ELISA) that is able to detect
pg/mL amounts of sTREM-1 in serum of patients. Using
this new TREM-1 speciﬁc assay, we assessed the amount of
sTREM-1 released in 12 patients suﬀering from COPD and
10 healthy individuals for sTREM-1 and indeed found ele-
vated levels of sTREM-1 in patients COPD, which correlated
with disease severity.
2. PATIENTS, MATERIALS, AND METHODS
2.1. Patients
Twelve patients with COPD, all current smokers or exsmok-
ers, were recruited on the basis of their clinical diagnosis and
lungfunctionimpairment.Noneofthepatientshadlungdis-
eases other than COPD and all were in a stable clinical con-
dition for at least 3 month. The control group comprised 10
healthy nonsmoking individuals without the sign of airway
obstruction and other signiﬁcant illness. The study was ap-
proved by the local Ethics Committee.
All patients with COPD were under treatment with in-
haled β2-adrenoceptor agonists and/or anticholinergics, 3
patients were treated additionally with inhaled steroids, 3
with systemic steroids, and 2 with additional theophyllin,
whereas the healthy control subjects did not have medica-
tion. Regarding baseline characteristics, there were no other
signiﬁcant diﬀerences between groups, except for lung func-
tion (Table 1).
2.2. Assessmentoflungfunction
Lung function measurements including the determination
of forced expiratory volume in 1s (FEV1), forced vital ca-
pacity (FVC), residual volume (RV), intrathoracic gas vol-
ume (ITGV), and single breath diﬀusion capacity for car-
bon monoxide (DLCO) were performed following estab-
lishedguidelines[29–31]usingstandardequipment(Master-
lab, Jaeger, H¨ ochberg, Germany). Bronchodilator responses
were quantiﬁed as absolute and percent increase of FEV1
measured 15minutes after inhalation of 200μg salbutamol.
2.3. Transfectants
Full-length cDNA encoding TREM-1 cloned in the eukary-
ontic expression vector pcDNA3 (Invitrogen) were stably
transfected in HEK293 cells with Fugene 6 (Roche) accord-
ing to standard protocols. The TREM-1cDNAs have been
described previously [11]. Transfectants were obtained after
G418 selection.
The production recombinant TREM-1::IgG1 fusion pro-
tein has been described previously [14].
2.4. Monoclonalantibodies
TREM-1 speciﬁc monoclonal antibodies (clone 6B1) were
raised by repeated immunization of BALB/c mice with a
recombinant TREM-1::IgG1 fusion protein according to
standard procedures. Hybridoma supernatants were ﬁrst
screened by ELISA against TREM-1::IgG1 and human IgG
(Sigma-Aldrich, Taufkirchen), respectively. Supernatants re-
acting against TREM-1::IgG1, but not IgG, were subcloned
twice and further screened by ﬂow cytometry using TREM-
1-transfected 293 cells. Antibodies (Abs) were puriﬁed by
aﬃnity chromatography on a protein G-Sepharose column.
The mAb clones 1C5 and 6B1 were of isotype IgG1.
2.5. DetectionofsolubleTREM-1byELISA
For the detection of soluble TREM-1 (sTREM-1), anti-
TREM-1 (6B1) mAb was coated at 0.5μg/mL in PBS, then
blockedbyadditionof100μLof15%BSAfor2hoursat37
◦C
and washed. Afterward the standard (recombinant TREM-
1::IgG1 in 7.5% BSA-PBS) and the samples were added and
the plates were incubated for 2hours at 37
◦C. For analysis of
patient samples, sera were diluted 1 : 10 in 5% BSA prior to
addition to the plates. After incubation, plates were washed
and the biotinylated detection polyclonal Ab anti-TREM-1
(R&D Systems) at 5μg/mL in 7.5% BSA-PBS was added for
2hours at 37
◦C. Plates were then washed and streptavidine-
HRP (1 : 8000 in 7.5% BSA-PBS) was added for 1hour
at 37
◦C. Plates were then washed again and developed us-
ing the Tetramethylbenzidine Peroxidase Substrate System
(KPL, Gaithersburg, Md). The absorbance was measured at
450nm. Results are shown as means with SD of triplicates.
The lower detection limit was deﬁned by 2x SD of the blank
values (5pg/mL). The recovery rate was 90.6+/ − 1%. In-
traassay variation was 7 + / − 1%, interassay variation was
6+/ −5%.
2.6. Statisticalprocedures
Mean values, medians, and standard deviation (SD) were
computed. sTREM-1 levels were compared between groups
using Mann-Whitney-U test. Lung function and otherMarkus P. Radsak et al. 3
Table 1: Patients’ characteristics (ND not done).
Control COPD
Sex (f/m) 4/6 5/7
Age (y) 51 ±14 56 ± 10
Height (cm) 171 ±9 169 ±8
BMI (kg/m2)2 6 .9 ±6.12 3 .3 ±4.5
Pack years of smoking 0 30 ±12
∗
FEV1 (L) 3.52 ±0.97 1.51 ±0.68
∗
FEV1 (%predicted) 103 ±13 51 ±20
∗
FEV1/FVC (%) 73 ±45 2 ±10
∗
ΔFEV1 Salbutamol (%) N.D. 3.8 ± 1.6
RV (%predicted) 95 ±49 165 ±63
∗
ITGV (L) 3.57 ±1.64 .32 ±1.4
∗
DLCO (%predicted) 94 ±66 1 ±12
∗
sTREM-1 (ng/mL) 0.25 (0–5.9) 11.68 (6.2–41.9)
∗
∗ For abbreviations, see text. Mean values ± SD are given. For sTREM-1 median and range are given ∗P<. 05 regarding the comparison between groups.
values were compared between groups using unpaired t-test.
Correlation analysis was performed by Spearman’s rank cor-
relation. Statistical signiﬁcance was assumed for P<. 05.
3. RESULTS
3.1. DetectionofsTREM-1inserumbyELISA
To evaluate the newly developed assay TREM-1-IgG recom-
binant human TREM-1::IgG1 and serum form a patient
with sepsis were analyzed in serial dilutions since high levels
of sTREM-1 have been described in sepsis previously [22].
As depicted in Figure 1, the assay allowed the detection of
sTREM-1 down to 5pg/mL sTREM-1 concluding that this
new ELISA protocol is a suitable tool to investigate the sig-
niﬁcance of sTREM-1 in patients.
3.2. SerumlevelsofsTREM-1areelevated
inpatientswithCOPD
None of the control patients showed airway obstruction
(Table 1), whereas COPD patients showed a signiﬁcantly de-
creased FEV1 and FEV1% predicted (Table 1). According to
GOLD criteria 2, patients were categorized as stage I (mild),
3 patients as stage II (moderate), 6 patients as stage III (se-
vere) and 1 patients as stage IV (very severe) [32]. COPD pa-
tients also showed a signiﬁcant increase in RV (P = .015)
as well as ITGV (P = .035) and a signiﬁcant decrease in
DLCO(P<. 001)comparedtothecontrolsubjects(Table 1).
None of the COPD patients showed a positive response to
salbutamol, deﬁned as an increase in FEV1 of at least 15%
and 200mL. Serum levels of sTREM-1 were signiﬁcantly
(P = .019) increased in patients with COPD compared to
controls. In contrast, in healthy subjects sTREM-1 was de-
tectable in serum samples of only 6 subjects (Figure 2).
3.3. Relationshipbetweenserumlevelsof
sTREM-1andclinicalparameters
Levels of sTREM-1 in serum were correlated with absolute
FEV1 (r =− 0.74, P = .001), FEV1% predicted (r =− 0.78,
P<. 001) (Figure 3)a n dF E V 1%V C( r =− 0.82, P<. 001).
Also signiﬁcant correlations were detected to RV (r = 0.48,
P = .024), DLCO (r =− 0.78, P<. 001) and VC % predicted
(r =− 0.47, P = .028). No relationship was found between
sTREM-1 and BMI (r =− 0.28, P = .215), age of the patient
(r = 0.11, P = .64), height (r =− 0.13, P = .553), or weight
(r =− 0.39, P = .069).
Duetothelimitednumberofpatientsinourstudy,itwas
not possible to analyze correlations between lung function
parameter and sTREM-1 levels.
4. DISCUSSION
In the present study, we show that sTREM-1 levels in serum
are elevated in patients with COPD compared to healthy,
nonsmoking controls. Furthermore, we demonstrate that
serum levels of sTREM-1 are correlated with disease sever-
ity.
COPD is a multicomponent disease which includes in-
ﬂammatory changes in the lung. Inﬂammatory cells in lungs
of patients with COPD are mainly neutrophil granulocytes
and inﬂammation in the lung is more pronounced with
worse lung function [33]. Also, numbers of neutrophils in
sputum correlate with disease progression [34]. In many
patients, COPD has also signiﬁcant systemic consequences.
This includes loss of lean bodymass, cardiovascular eﬀects,
osteoporosis, muscle wasting but also a systemic inﬂamma-
tory response. Indeed, in patients with COPD, even during
stable disease, there is an increased number of leukocytes in
peripheral blood [35, 36] Peripheral neutrophils from pa-
tients with COPD show enhanced chemotaxis and extracel-
lular proteolysis [37] ,p r o d u c em o r er e a c t i v eo x y g e ns p e c i e s
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Figure 1: ELISA for sTREM-1. (a) Titration of recombinant human TREM-1::IgG1 either in the absence (ﬁlled symbols) or presence of
















Figure 2: Concentration of sTREM-1 in serum of healthy controls
(controls) and patients with COPD.
molecules [39]. Also increased levels of TNF-α, IL-6, IL-8,
C-reactive protein, and ﬁbrinogen in serum can be detected
in serum of patients with stable COPD and some of these
systemic inﬂammatory changes seem to be related to disease
severity [4] and correlate with severity of systemic conse-
quences like muscle wasting [40].
In the present study, we describe a new ELISA for the
detection of sTREM-1 in serum. In contrast, most previous
studies have used an immunodot blot technique for the de-
tection of sTREM-1 [22, 25, 41]. This technique allows the
sensitive detection of sTREM-1 in body ﬂuids. However, for
assessmentof sTREM-1in a clinical routine setting detection
by sandwich ELISA has the advantage that greater sample
numbers may be processed simultaneously with increased
speciﬁcity. Therefore, we developed a new sensitive ELISA
using a monoclonal antibody to capture sTREM-1 in sera of
patients and a polyclonal anti-TREM-1 for detection. Using
ournewsandwich-ELISAprotocol,weestablishedastandard
laboratory method for the sensitive and speciﬁc detection of
sTREM-1 in body ﬂuids avoiding the pitfalls and potential
disadvantagesassociatedwiththeimmunodotblottechnique
used so far. When analyzing serum samples from patients
with stable COPD, we were able to detect sTREM-1 in all
samples. In contrast, in samples from healthy control sub-
jects sTREM-1 was only detectable in 6 of the patients and
onlyinverylowamounts.Inlinewithpreviousdataobtained
from patients suﬀering from severe inﬂammatory disorders
like pneumonia or sepsis [22–24], our data indicate that
sTREM-1 might be a result of neutrophil activation also in
COPD patients. The current view in terms of the pathophys-
iology suggests that sTREM-1 is an anti-inﬂammatory medi-
ator of sepsis [42], released as a counter regulator of TREM-
1 mediated activation. Our recent results demonstrating that
sTREM-1 interferes with the TREM-1/ligand interaction of
neutrophil and platelets support this view [14].
Previous studies have described increased levels of
sTREM-1 in patients with sepsis [22], pneumonia [20]
but also exacerbated asthma and COPD. By using an im-
munoblot technique, Phua et al. found increased levels
of sTREM-1 especially in patients with COPD during an
Anthonisen-type 1 exacerbation [41].
The authors speculated that the patients with type 1 ex-
acerbation shad higher airway bacterial loads, which trig-
gered systemic inﬂammation and increased sTREM-1 levels
[43, 44]. In the present study, increased levels of sTREM-1,
measured by ELISA, were detected even in patients with sta-
ble disease. This could be due to an increased sensitivity of
the newly introduced ELISA.
Potential explanations for the increased levels of sTREM-
1 observed in this group of stable patients with COPD could
be persistent bacterial colonization of the airways, which has
been demonstrated by several groups [6–9]. These coloniza-
tions can be associated with elevated levels of inﬂamma-
tory mediators like IL-8, LTB4, and TNF-α in the lungs ofMarkus P. Radsak et al. 5




















































































Figure 3: Relationship between sTREM-1 serum levels and absolute FEV1(panel A), FEV1% predicted (panel B), residual volume (RV) %
predicted (panel C), and diﬀusion capacity (DLCO) % predicted (panel D). Control subjects are represented by open circles, patients with
COPD by closed circles.
patients with clinically stable disease [10]. In addition, in-
creased plasma ﬁbrinogen and IL-6 levels are detectable in
these bacterially colonized patients suggesting that coloniza-
tion contributes to systemic inﬂammation [44]. In patients
with more advanced disease, higher levels of serum CRP
have been described, suggesting increased systemic inﬂam-
matory reaction [45–47]. As sTREM-1 can be induced by
increased systemic inﬂammation [20, 23, 24] the increased
sensitivity of our ELISA assay could be the reason for in-
creased levels of sTREM-1 detected in the present study
population.
Additionally, we found a correlation of sTREM-1 levels
in serum with disease severity, described by impaired lung
function, in the COPD group. This was the case when ab-
solute and relative values of FEV1 as markers for airway ob-
struction, RV for hyperinﬂation, and also diﬀusion capac-
ity as a marker for emphysema were analyzed. No correla-
tions were found for age, height, weight, or BMI. Also lev-
els of sTREM-1 in serum were independent for medication
used by patients. Some of the patients with more severe dis-
ease (GOLD stadium III–IV) treated with systemic steroid
still showed increased levels of sTREM-1 in serum. Although
this analysis is somewhat limited by low numbers of patients
and control sTREM-1 may yet be another systemic marker
correlated with disease severity.
In summary we show increased serum levels of sTREM-
1 in patients with clinical stable COPD, and a correlation
between serum levels and disease severity. sTREM-1 might
be a useful marker for systemic inﬂammation in patients
with COPD. Further prospective studies are needed to eval-
uate the true diagnostic value of sTREM-1 in this patient
population.
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